Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products

Abstract Background Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigati...

Full description

Bibliographic Details
Main Authors: Anjali Nagpal, Austin G. Milton, Simon A. Koblar, M. Anne Hamilton-Bruce
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Stem Cell Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13287-021-02147-6
id doaj-025f7192fd16410c9a892234036dc7cb
record_format Article
spelling doaj-025f7192fd16410c9a892234036dc7cb2021-01-31T12:16:04ZengBMCStem Cell Research & Therapy1757-65122021-01-011211710.1186/s13287-021-02147-6Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy productsAnjali Nagpal0Austin G. Milton1Simon A. Koblar2M. Anne Hamilton-Bruce3Stroke Research Programme, Adelaide Medical School, University of AdelaideStroke Research Programme, The Queen Elizabeth HospitalStroke Research Programme, Adelaide Medical School, University of AdelaideStroke Research Programme, Adelaide Medical School, University of AdelaideAbstract Background Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigational cell therapies into viable medical products. Methods We developed a checklist using a mixed methodology approach to evaluate the impact of study design, regulatory policy, ethical, and health economic considerations for efficient implementation of early phase cell therapy studies. Results The checklist comprises a series of questions arranged under four domains: the first concerns study design such as characterization of target study population, trial design, endpoints and operational fit of dosage, time, and route of administration to target populations. A second domain addresses the data package required for regulatory approval relevant to the intended use (allogeneic/autologous; homologous/non-homologous; nature of cell processing). The third domain comprises patient involvement to ensure relevant data is collected via targeted study design. The final domain requires the team to determine the critical data elements that could be built into study design to enable health economic data collection to be started at an early phase of the study. Conclusions The CT2S checklist can help to determine areas of expertise gaps and enable research groups to appropriately allocate resources for capacity building. Use of this checklist will allow identification of key areas where trial planning needs to be optimized, as well as helping to identify resources that need to be secured. The CT2S checklist can also serve as a general cell therapy research decision aid to improve research output and accelerate new cell therapy development.https://doi.org/10.1186/s13287-021-02147-6Clinical translationCell therapies in strokeChecklistStudy designRegulatoryPatient and Public Involvement in Research (PPIR)
collection DOAJ
language English
format Article
sources DOAJ
author Anjali Nagpal
Austin G. Milton
Simon A. Koblar
M. Anne Hamilton-Bruce
spellingShingle Anjali Nagpal
Austin G. Milton
Simon A. Koblar
M. Anne Hamilton-Bruce
Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products
Stem Cell Research & Therapy
Clinical translation
Cell therapies in stroke
Checklist
Study design
Regulatory
Patient and Public Involvement in Research (PPIR)
author_facet Anjali Nagpal
Austin G. Milton
Simon A. Koblar
M. Anne Hamilton-Bruce
author_sort Anjali Nagpal
title Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products
title_short Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products
title_full Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products
title_fullStr Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products
title_full_unstemmed Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products
title_sort clinical translation of cell therapies in stroke (ct2s) checklist—a pragmatic tool to accelerate development of cell therapy products
publisher BMC
series Stem Cell Research & Therapy
issn 1757-6512
publishDate 2021-01-01
description Abstract Background Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigational cell therapies into viable medical products. Methods We developed a checklist using a mixed methodology approach to evaluate the impact of study design, regulatory policy, ethical, and health economic considerations for efficient implementation of early phase cell therapy studies. Results The checklist comprises a series of questions arranged under four domains: the first concerns study design such as characterization of target study population, trial design, endpoints and operational fit of dosage, time, and route of administration to target populations. A second domain addresses the data package required for regulatory approval relevant to the intended use (allogeneic/autologous; homologous/non-homologous; nature of cell processing). The third domain comprises patient involvement to ensure relevant data is collected via targeted study design. The final domain requires the team to determine the critical data elements that could be built into study design to enable health economic data collection to be started at an early phase of the study. Conclusions The CT2S checklist can help to determine areas of expertise gaps and enable research groups to appropriately allocate resources for capacity building. Use of this checklist will allow identification of key areas where trial planning needs to be optimized, as well as helping to identify resources that need to be secured. The CT2S checklist can also serve as a general cell therapy research decision aid to improve research output and accelerate new cell therapy development.
topic Clinical translation
Cell therapies in stroke
Checklist
Study design
Regulatory
Patient and Public Involvement in Research (PPIR)
url https://doi.org/10.1186/s13287-021-02147-6
work_keys_str_mv AT anjalinagpal clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts
AT austingmilton clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts
AT simonakoblar clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts
AT mannehamiltonbruce clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts
_version_ 1724317355650056192